The role of Fusobacterium colorectal cancer

Fusobacterium nucleatum is a bacterium that usually lives in the mouth. However, it can migrate to the colon, where it fuels the growth and progression of Fusobacterium colorectal cancer.

The presence of specific bacteria within colon tumors appears to affect cancer biology, influencing how tumors develop, grow, and respond to treatment. The discovery has opened new avenues for understanding why some colon cancers behave more aggressively than others.

Understanding the relationship between bacteria and cancer is crucial because it is a potential target for cancer treatments. Unlike genetic mutations that are difficult to reverse, medications could potentially address the bacterial infections. This creates opportunities for combination therapies that attack both cancer cells and the germs that support them.

Fusobacterium colorectal cancer refers to colon tumors that contain large amounts of Fusobacterium nucleatum bacteria mixed in with the cancer cells. It is not an official cancer type or diagnosis; rather, the bacterial presence is a biomarker or characteristic of the tumor.

Fusobacterium nucleatum bacteria are usually found in the oral cavity and are rare in the digestive system of healthy people. However, studies show that 38.9% of those with colorectal cancer have the bacteria present in stool or tumor samples.

These tumors often look different under the microscope and may behave differently from colon cancers without the bacteria. They may have different genetic changes and respond differently to treatments.

Fusobacterium nucleatum may trigger and worsen colon cancer in several ways.

Firstly, it creates long-lasting inflammation in the colon, which can damage DNA and lead to the genetic changes that turn cells into cancer cells.

The bacteria also help cancer cells hide from the body’s immune system. Normally, immune cells would recognize and destroy cancer cells, but the bacteria can interfere with the process. It attracts cells that suppress immune responses while blocking the immune cells that would normally fight cancer.

Additionally, the bacteria make it easier for cancer cells to invade nearby tissues and spread to other parts of the body. They break down the connections between healthy cells and help cancer cells move around more easily, which can lead to cancer spreading beyond the original tumor site.

The symptoms of Fusobacterium colorectal cancer are the same as those of other types of colon cancer, since the bacterial presence does not cause unique signs.

People should see a doctor if they notice persistent changes in their bowel habits, blood in the stool, or any other symptoms of colorectal cancer.

Having family members with colon cancer or inflammatory bowel disease makes it more urgent to get concerning symptoms checked.

Individuals 45 and older should talk with their doctors about colon cancer screening. Medical guidelines recently lowered the recommended starting age from 50.

Diagnosing Fusobacterium colorectal cancer requires standard colon cancer tests and special testing to find the bacteria. The process typically begins with a colonoscopy, during which doctors use a flexible tube equipped with a camera to examine the inside of the colon and collect small tissue samples from any suspicious areas.

Imaging tests, such as CT scans and MRIs, help doctors see how far the cancer has spread. Blood tests may show anemia, signs of inflammation, or tumor markers that can indicate cancer.

Special laboratory tests on the tissue samples can identify whether Fusobacterium nucleatum is present in the tumor. These tests use advanced molecular techniques to detect and measure the bacteria within the cancer tissue.

Treatment for Fusobacterium colorectal cancer currently follows standard colorectal cancer protocols. Surgery to remove the tumor and nearby lymph nodes is the primary treatment for cancer that has not spread. Chemotherapy typically uses combinations of drugs such as 5-fluorouracil, oxaliplatin, and irinotecan.

While targeting the bacteria is a promising therapeutic route, researchers are still working to develop effective treatments that target them.

Research is exploring whether antibiotics that kill Fusobacterium nucleatum could enhance standard cancer treatments. Metronidazole, an antibiotic that targets this type of bacteria, may enhance the effectiveness of chemotherapy in bacteria-positive tumors.

Immunotherapy treatments that help the immune system fight cancer are another potential option. Some people with bacteria-positive tumors may benefit from specific combinations of immunotherapy drugs.

The outlook for Fusobacterium colorectal cancer depends on how advanced the cancer is, the person’s overall health, and specific characteristics of the tumor.

Early-stage colorectal cancer generally has a better outlook than advanced disease. Localized cancers have a 5-year survival rate of around 90%, dropping to 13 to 18% for those that have spread to distant sites.

It may not be possible to prevent all cases of Fusobacterium colorectal cancer. However, the following strategies may help:

Fusobacterium colorectal cancer is a type of colon cancer characterized by the presence of Fusobacterium nucleatum bacteria within the tumors. The bacteria appear to influence how cancer develops, grows, and responds to treatment.

Current treatments follow standard approaches for colon cancer, with research exploring bacterial targeting as an additional therapy.

The outlook for Fusobacterium colorectal cancer continues to improve as research advances understanding of how bacteria and cancer interact. Prevention strategies that focus on oral hygiene, healthy lifestyle choices, and regular screenings are essential for reducing risk and improving outcomes.